Attending the I.N.N.O.V.A.T.E meeting means joining a transformative forum of global experts and researchers dedicated to advancing neoadjuvant immunotherapy as a practice-changing treatment approach and drug development platform. The meeting will highlight progress in clinical applications, the harmonization of pathology as a surrogate endpoint, and personalized treatment approaches, while providing insights into translational research and cancer-specific developments.

The meeting aims to drive innovation in neoadjuvant immunotherapy by addressing critical areas such as the integration of neoadjuvant therapies into standard practice and their role as a platform for developing new drugs. Pathologic response has emerged as a key endpoint in this space, and harmonizing its evaluation across cancers is critical for advancing the field. Moreover, neoadjuvant therapies offer opportunities to personalize treatment approaches by tailoring interventions to the biology and immune landscape of each tumor.

Cancer-specific updates will provide a deeper understanding of the evolving role of neoadjuvant immunotherapy in different tumor types, while translational insights will focus on biomarker development to guide treatment decisions and predict outcomes across cancers. These insights are vital for optimizing patient selection, enhancing therapeutic efficacy, and guiding future therapeutic development.

The I.N.N.O.V.A.T.E meeting will feature leading experts from around the world, delivering keynote presentations, panel discussions, and interactive sessions. Topics will include pathology harmonization, surrogate endpoints, biomarker research, and patient-reported outcomes, along with disease-specific overviews that reflect the latest advancements in neoadjuvant immunotherapy. This comprehensive agenda aims to foster collaboration, drive innovation, and shape the future of cancer care.

Join us at #I.N.N.O.VA.T.E meeting!